SciSparc EBITDA 2017-2024 | SPRC

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

SciSparc ebitda from 2017 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

SciSparc ebitda from 2017 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$70.1B
Zoetis (ZTS)	$68.6B
Takeda Pharmaceutical (TAK)	$47.3B
Daiichi Sankyo, - (DSNKY)	$46.4B
BeOne Medicines - (ONC)	$33.9B
Sandoz Group AG (SDZNY)	$27.3B
Summit Therapeutics (SMMT)	$20B
Merck (MKKGY)	$16.3B
Shionogi (SGIOY)	$14.6B
United Therapeutics (UTHR)	$13.9B
Neurocrine Biosciences (NBIX)	$13.6B
Orion OYJ (ORINY)	$11.3B
IPSEN (IPSEY)	$11.1B
Madrigal Pharmaceuticals (MDGL)	$9.4B
Eisai (ESAIY)	$9.2B
Corcept Therapeutics (CORT)	$7.3B
Grifols, S.A (GRFS)	$6.8B
Ionis Pharmaceuticals (IONS)	$6.7B
Stevanato Group S.p.A (STVN)	$6.6B
Ono Pharmaceutical (OPHLF)	$5.7B
Hikma Pharmaceuticals Plc (HKMPF)	$5.4B
Soleno Therapeutics (SLNO)	$3.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.9B
Crinetics Pharmaceuticals (CRNX)	$2.9B
NewAmsterdam Pharma (NAMS)	$2.8B
Hypermarcas (HYPMY)	$2.8B
Catalyst Pharmaceuticals (CPRX)	$2.4B
Centessa Pharmaceuticals (CNTA)	$2.2B
Ocular Therapeutix (OCUL)	$2.1B
Dyne Therapeutics (DYN)	$1.9B